Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's latest updates on AW21003, a compound targeting PTSD. Developed in partnership with Awakn Life Sciences, AW21003 aims to address trauma-related mental health disorders, which affect millions across the US, UK, and Europe.
Tennyson discussed the collaboration with the University of Nottingham, renowned for its neuroscience expertise. The initial findings suggest that AW21003 promotes pro-social behaviours, a critical factor in PTSD treatment. Moreover, the compound shows indications of a potentially safer profile compared to existing treatments.
Looking ahead, Graft Polymer plans to expand its aminoindane program, synthesizing and screening additional compounds to identify the most promising candidates for clinical advancement.